These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 8575036)

  • 21. Antisecretory and antiulcer activities of a novel proton pump inhibitor AG-1749 in dogs and rats.
    Satoh H; Inatomi N; Nagaya H; Inada I; Nohara A; Nakamura N; Maki Y
    J Pharmacol Exp Ther; 1989 Feb; 248(2):806-15. PubMed ID: 2537418
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Similarities and differences in the properties of substituted benzimidazoles: a comparison between pantoprazole and related compounds.
    Kromer W
    Digestion; 1995; 56(6):443-54. PubMed ID: 8536813
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effects of acid-inhibitory antiulcer drugs on mucin biosynthesis in the rat stomach.
    Ichikawa T; Ishihara K; Saigenji K; Hotta K
    Eur J Pharmacol; 1994 Jan; 251(1):107-11. PubMed ID: 7907983
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of 2-[[(4-fluoroalkoxy-2-pyridyl)methyl]sulfinyl]-1H- benzimidazoles as antiulcer agents.
    Kubo K; Oda K; Kaneko T; Satoh H; Nohara A
    Chem Pharm Bull (Tokyo); 1990 Oct; 38(10):2853-8. PubMed ID: 2076571
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synthetic study of 2-[(6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9- yl)-sulfinyl]-1H-benzimidazole analogs and their biological properties as novel proton pump inhibitors.
    Yamada S; Goto T; Yamaguchi T; Aihara K; Kogi K; Narita S
    Chem Pharm Bull (Tokyo); 1995 Mar; 43(3):421-31. PubMed ID: 7774025
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacokinetics, metabolism and interactions of acid pump inhibitors. Focus on omeprazole, lansoprazole and pantoprazole.
    Andersson T
    Clin Pharmacokinet; 1996 Jul; 31(1):9-28. PubMed ID: 8827397
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Synthesis and drug efficacy validations of racemic-substituted benzimidazoles as antiulcer/antigastric secretion agents.
    Radhamanalan R; Alagumuthu M; Nagaraju N
    Future Med Chem; 2018 Aug; 10(15):1805-1820. PubMed ID: 30019937
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitions of acid secretion by E3810 and omeprazole, and their reversal by glutathione.
    Fujisaki H; Shibata H; Oketani K; Murakami M; Fujimoto M; Wakabayashi T; Yamatsu I; Yamaguchi M; Sakai H; Takeguchi N
    Biochem Pharmacol; 1991 Jul; 42(2):321-8. PubMed ID: 1650210
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chemistry of covalent inhibition of the gastric (H+, K+)-ATPase by proton pump inhibitors.
    Shin JM; Cho YM; Sachs G
    J Am Chem Soc; 2004 Jun; 126(25):7800-11. PubMed ID: 15212527
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparative pharmacokinetic/pharmacodynamic study of proton pump inhibitors, omeprazole and lansoprazole in rats.
    Katashima M; Yamamoto K; Sugiura M; Sawada Y; Iga T
    Drug Metab Dispos; 1995 Jul; 23(7):718-23. PubMed ID: 7587960
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synthesis or rupture: duration of acid inhibition by proton pump inhibitors.
    Sachs G; Shin JM; Pratha V; Hogan D
    Drugs Today (Barc); 2003 Mar; 39 Suppl A():11-4. PubMed ID: 12712216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The pharmacology of the gastric acid pump: the H+,K+ ATPase.
    Sachs G; Shin JM; Briving C; Wallmark B; Hersey S
    Annu Rev Pharmacol Toxicol; 1995; 35():277-305. PubMed ID: 7598495
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Acid secretion inhibition with new mechanisms of action: substituted benzimidazole].
    Olbe L; Lind T; Carlsson E; Cederberg C; Helander H; Wallmark B
    Schweiz Med Wochenschr; 1984 May; 114(20):683-5. PubMed ID: 6740286
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of acid pump antagonists (reversible PPIs).
    Wurst W; Hartmann M
    Yale J Biol Med; 1996; 69(3):233-43. PubMed ID: 9165692
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Antisecretory and antiulcer effect of T-330, a novel reversible proton pump inhibitor, in rats.
    Kinoshita M; Saito N; Tamaki H
    Eur J Pharmacol; 1997 Mar; 321(3):325-32. PubMed ID: 9085044
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Specific labelling of gastric H+,K+-ATPase by omeprazole.
    Fryklund J; Gedda K; Wallmark B
    Biochem Pharmacol; 1988 Jul; 37(13):2543-9. PubMed ID: 2839196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Gastroprotective and anti-secretory mechanisms of 2-phenylquinoline, an alkaloid isolated from Galipea longiflora.
    Breviglieri E; Mota da Silva L; Boeing T; Somensi LB; Cury BJ; Gimenez A; Cechinel Filho V; de Andrade SF
    Phytomedicine; 2017 Feb; 25():61-70. PubMed ID: 28190472
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics and effect on caffeine metabolism of the proton pump inhibitors, omeprazole, lansoprazole, and pantoprazole.
    Andersson T; Holmberg J; Röhss K; Walan A
    Br J Clin Pharmacol; 1998 Apr; 45(4):369-75. PubMed ID: 9578184
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The H+, K(+)-ATPase inhibitor pantoprazole (BY1023/SK&F96022) interacts less with cytochrome P450 than omeprazole and lansoprazole.
    Simon WA; Büdingen C; Fahr S; Kinder B; Koske M
    Biochem Pharmacol; 1991 Jul; 42(2):347-55. PubMed ID: 1650212
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evidence for acid-induced transformation of omeprazole into an active inhibitor of (H+ + K+)-ATPase within the parietal cell.
    Wallmark B; Brändström A; Larsson H
    Biochim Biophys Acta; 1984 Dec; 778(3):549-58. PubMed ID: 6095911
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.